Presentations
Please note these are in order of the speaker’s last name and some speakers have opted not to share slides.
International Keynote Speakers
What Adult Transplanters Can Learn from Paediatric Transplanters and Vice Versa
Prof Catherine Bollard – Senior Vice President, Children’s National Hospital
Managing CAR T Toxicities in Myeloma
Prof Hermann Einsele – Professor of Internal Medicine and Director of Medicine II, University Hospital Würzburg
Pending sharable file
Lunch ‘n’ Learn – Myeloma CAR T in the real world
Prof Hermann Einsele – Professor of Internal Medicine and Director of Medicine II, University Hospital Würzburg
Pending sharable file
Beyond Protocol: Personalised preparation and parallel planning for transplant and cell therapy
Sara Main – Lead Nurse, BMT and Cell Therapy, University Hospital Southampton NHS Trust
TCT science and capability building
A/Prof Folashade Otegbeye – Transplant Specialist and Facility Director of the Therapeutic Products Program, Fred Hutch Cancer Center
Available on request
– please email info@anztct.org.au
Allogeneic Donor Selection – Contemporary Guidelines from NMDP/CIBMTR
Stephen Spellman – Vice President of Research and Senior Scientific Director, CIBMTR NMDP
What will the Myeloma Treatment Algorithm be in 2027?
Prof Evangelos Terpos – Professor of Haematology, Department of Clinical Therapeutics, University of Athens School of Medicine
Sequencing Bispecifics with CAR T
Dr Julie Vose – George and Peggy Payne Distinguished Chair of Oncology; Professor, UNMC Division of Hematology; Director, Lymphoma Research Group
Speakers
ANZTCT Benchmarking and CQR government reporting
A/Prof Edward Abadir – Clinical and Laboratory Staff Specialist Haematology, Royal Prince Alfred Hospital
Oral Abstract
Cassie Abbott – CAR-T Nurse Practitioner Candidate, Alfred Health
Building a Skilled and Confident CAR-T Nursing Workforce: Assessing the Impact of Nurse-led CAR-T Education
Patient-led story
Chantelle Asciak
ANZTCT Practice Statement – Optimising Pre-TCT AML Care
A/Prof Ashish Bajel – Clinical and BMT Haematologist, Royal Melbourne Hospital and Peter MacCallum Cancer Centre
Oral Abstract: Presidential
Elias Biris – Senior Clinical Pharmacist, Royal Adelaide Hospital
Weight-adjusted ATG dosing improves relapse-free survival in obese allo-HSCT recipients
Bispecifics in the Elderly
Dr Adam Bryant – Senior Staff Specialist Haematologist, Liverpool Hospital
Oral Abstracts
Dr Katherine Cummins – Clinical Haematologist, Peter MacCallum Cancer Centre & The Royal Melbourne Hospital
Trial in progress – Early clinical data From “PLATYPS”, a first-in-human clinical trial of an Australian-developed and manufactured CD19-targeting CAR-T cell product (PMCC-COE19)
No sharable file
ANZTCT Data Enhancement Opportunity: Integrating higher quality HLA data (IHWG)
Dr Dianne De Santis – Clinical Scientist
Who Gets Left Behind? Employment Inequity and Financial Toxicity After Allogeneic Stem Cell Transplant
Dr Genevieve Douglas – Haematologist and Bone Marrow Transplant Physician, Austin and Eastern Health
Oral Abstract
Dr Salvatore (Sam) Fiorenza – Consultant Haematologist, The Alfred Hospital
Vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout, in patients with relapsed/refractory B cell Non-Hodgkin Lymphoma (ANTLER phase 1 clinical trial)
ANZTCT Practice Statement – Optimising VOD Outcomes following TCT
A/Prof Shaun Fleming – Head of Myeloid Diseases Service, Alfred Health
Debate (Negative): CAR T is the ‘B-ALL’ and end-all – consolidation is unnecessary
A/Prof Shaun Fleming – Head of Myeloid Diseases Service, Alfred Health
Pending sharable file
Oral Abstract
Lotte Stubkjaer Fog – Medical Physicist, The Alfred Hospital (on behalf of Dr Sarah Li)
Total Body Irradiation in Australia and New Zealand: A 2024 Practice Survey on Changing Patterns of Care
Oral Abstract
Dr Kate Graham – Clinical Dietician, Peter MacCallum Cancer Centre
Development of a nutrition care pathway for haematology cancer patients undergoing chimeric antigen receptor T-Cell (CAR-T) therapy
Oral Abstract: Presidential
Prof Nada Hamad – President, ANZTCT
Allogeneic stem cell transplantation for sickle cell disease in Australia and New Zealand: outcomes, unmet demand and the arrival of gene therapy
Emerging novel agents in CLL
Dr Sasanka Handunnetti – Clinical Haematologist, Princess Alexandra Hospital
Stem Cell Donors executive update
Garth Healey – Chief Operating Officer, Stem Cell Donors Australia (on behalf of Lisa Smith)
ANZTCT Practice Statement – Optimising CMV Outcomes in TCT
A/Prof Andrea Henden – Staff Specialist, Haematology and Bone Marrow Transplantation, Royal Brisbane and Women’s Hospital
Combining Chemotherapy and Bispecifics
Prof Mark Hertzberg AM – Previous Head of Haematology, Prince of Wales Hospital and University of NSW, Sydney
Debate (Negative): CAR-T before the Horse (bsAb)?
Prof Joy Ho – Clinical Professor, University of Sydney and Senior Staff Specialist, Royal Prince Alfred Hospital
Pending sharable file
Oral Abstract: Presidential
Dr Miles Horton – Clinician-Scientist, Walter and Eliza Hall Institute and Paediatrics Trainee, Royal Children’s Hospital, Melbourne
Multiplex prime editing enables safe, drug-controllable and immunosuppression-resistant T-cell therapies in vivo
The critical role of pharmacists in outpatient care
Dr Karim Ibrahim – Lead Pharmacist – Bone Marrow Transplant and Cellular Therapies, St Vincent’s Health Network, Sydney
Oral Abstract
Dr Karim Ibrahim – Lead Pharmacist – Bone Marrow Transplant and Cellular Therapies, St Vincent’s Health Network, Sydney
Evaluating the impact of a dedicated outpatient pharmacy clinic on medication safety and transitions of care for patients undergoing haematopoietic stem cell transplantation
The Hidden Half of Transplant: Supporting carers for better outcomes
- Georgia Janas – Social Worker, Metro North Health, Royal Brisbane and Women’s Hospital
- Amanda Mellow – Senior Social Worker Cancer Care, Royal Brisbane and Women’s Hospital
Assessment of Sarcopenia and Frailty in TCT Selection
Prof Nicole Kiss – Professor, Deakin University, School of Exercise and Nutrition Sciences
Feasibility of Outpatient Administration
Daniela Klarica – Multiple Myeloma Nurse Practitioner, The Alfred
Nursing Perspective: Quality of Life
Emily Knights – Lymphoma Care Nurse, Lymphoma Australia
Arrow Foundation update
Richelle Koller – Chief Executive Officer, Arrow Foundation
CLL Treatment Sequencing: Biomarkers, Resistance, and Strategy
Dr Masa Lasica – Co-Deputy Director of Haematology, St Vincent’s Hospital, Melbourne
Precision Dosing in Transplant: Right Drug, Right Patient, Right Time
Dr Rachael Lawson – Paediatric oncology clinician-researcher, Children’s Health Queensland
Debate (Affirmative): CAR-T before the Horse (bsAb)?
A/Prof Cindy Lee – Haematologist, Royal Adelaide and Queen Elizabeth Hospitals
Pending sharable file
Debate (Negative): PTCy reigns supreme: everyone should get PTCy
Dr Clinton Lewis – Haematologist and stem cell transplant physician, Auckland City Hospital
Pending sharable file
Lunch ‘n’ Learn: RSV in haematology patients: disease burden and prevention
Dr Tina Marinelli – Infectious diseases staff specialist, Royal Prince Alfred, Sydney
Bispecifics in Amyloidosis
Dr Olga Motorna – Clinical Haematologist, Eastern Health and Alfred Hospital
Oral Abstract
Nicole O’Leary – Nurse Practitioner, Peter MacCallum Cancer Centre
Intensive care unit utilisation amongst chimeric antigen receptor T-cell recipients: a single centre experience
No sharable file
Oral Abstract
Erica Patterson – Senior Clinician Physiotherapist, The Alfred
Early Identification Matters: Feasibility and Early Outcomes of a Nutrition and Exercise Program in Allogeneic Versus Autologous Stem Cell Transplant Recipients
Debate (Affirmative): CAR T is the ‘B-ALL’ and end-all – consolidation is unnecessary
Dr Madeleine Powys – Staff Specialist in Blood Transplant and Cell Therapies, The Children’s Hospital at Westmead
Pending sharable file
Oral Abstract
Dr Marzia Rahman – BMT Fellow, Alfred Health
Renal Function at Stem Cell Infusion Stratifies Risk of Cyclosporine Associated Acute Kidney Injury in PTCy Based AlloHSCT
Debate (Rux): Ruxolitinib vs ECP in GVHD management
Prof David Ritchie – Deputy Director of Clinical Haematology and Head of the BMT Service, the RMH and Peter MacCallum Cancer Centre and Director of the ACRF Translational Research Laboratory, the RMH
Pending sharable file
Bispecifics in High-Risk Disease
Prof Andrew Spencer – Head of Malignant Haematology, Transplantation and Cellular Therapy Service, The Alfred Hospital
Pending sharable file
Allograft and CAR T in highly refractory CLL (including Richter’s)
Prof Constantine Tam – Head of Lymphoma Service, Alfred Health
Debate (Affirmative): PTCy reigns supreme: everyone should get PTCy
A/Prof Siok Tey – Clinician scientist – Haematology, BMT and Cell Therapy, Royal Brisbane and Women’s Hospital
Pending sharable file
Demonstration of the new ANZTCT platform
- Dr Navid Toosi Saidy – CEO and Co-Founder, Propel Health AI
- Steven Tran – Tech Lead, ANZTCT Registry
Registry Update: The evolving ANZTCT Registry
Leonie Wilcox – Executive Director, ANZTCT Registry
IVIG in the Bispecific Era
Prof Erica Wood AO – Head of the Transfusion Research Unit, Monash University